Live Conference Call and Webcast at
8:30 AM ET
PALO
ALTO, Calif., Dec. 7, 2022
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR),
a commercial-stage biopharmaceutical company focused on the
development of innovative therapies for hepatitis delta virus (HDV)
and other serious diseases, today announced that it will host a
conference call on Thursday, December 8,
2022, at 8:30 AM Eastern Time, to discuss the results of
the Phase 3 D-LIVR study of lonafarnib-based treatments for
HDV.
The live and replayed webcast of the call will be available
through the company's website at www.eigerbio.com. To participate
in the live call by phone, dial (866) 374-5140 (U.S.) or (404)
400-0571 (International) and enter PIN 79797687#. The webcast will
be archived and available for replay for at least 90 days after the
event.
About Eiger
Eiger is a commercial-stage
biopharmaceutical company focused on the development of innovative
therapies to treat hepatitis delta virus (HDV) and other serious
rare diseases. The Eiger HDV platform includes two first-in-class
therapies in Phase 3 that target critical host processes involved
in viral replication. All five Eiger rare disease programs have
been granted FDA Breakthrough Therapy designation. For additional
information about Eiger and its clinical programs, please
visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-to-discuss-phase-3-d-livr-study-results-of-lonafarnib-based-treatments-in-hepatitis-delta-virus-hdv-on-thursday-december-8-2022-301697555.html
SOURCE Eiger BioPharmaceuticals, Inc.